How does MER's PE Ratio compare to its peers?

MER is good value based on its Price-To-Earnings Ratio (22.6x) compared to the peer average (22.9x).

How does MER's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

MER is expensive based on its Price-To-Earnings Ratio (22.6x) compared to the European Pharmaceuticals industry average (20.6x).

What is MER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate MER's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of MER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MER (CHF143.26) is trading below our estimate of [[fair value]] (CHF327.32)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Merck KGaA (BRSE:MER) - Stock Price, News & Analysis

MER Stock Overview

Operates as a science and technology company in Germany. More details

MER fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 56.2% below our estimate of its fair value

Earnings are forecast to grow 10.7% per year

Analysts in good agreement that stock price will rise by 32.1%

Risk Analysis

Shares are highly illiquid

Merck KGaA Competitors

Novartis

SWX:NOVN

CHF 182.4b

Roche Holding

SWX:ROG

CHF 203.6b

Dottikon ES Holding

SWX:DESN

CHF 3.2b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Price History & Performance

Summary of all time highs, changes and price drops for Merck KGaA
Historical stock prices
Current Share Price	€143.26
52 Week High	€0
52 Week Low	€0
Beta	0.71
11 Month Change	-7.82%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	189.42%

Recent updates

Shareholder Returns

	MER	CH Pharmaceuticals	CH Market
7D	0%	-3.1%	-2.2%
1Y	n/a	9.0%	6.2%

Return vs Industry: Insufficient data to determine how MER performed against the Swiss Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MER performed against the Swiss Market.

Price Volatility

Is MER's price volatile compared to industry and market?
MER volatility
MER Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	2.9%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: MER's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine MER's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1668	62,255	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Merck KGaA Fundamentals Summary

How do Merck KGaA's earnings and revenue compare to its market cap?
MER fundamental statistics
Market cap	CHF 56.94b
Earnings (TTM)	CHF 2.52b
Revenue (TTM)	CHF 19.61b

22.6x

P/E Ratio

2.9x

P/S Ratio

Is MER overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MER income statement (TTM)
Revenue	€20.96b
Cost of Revenue	€8.64b
Gross Profit	€12.33b
Other Expenses	€9.63b
Earnings	€2.70b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	6.20
Gross Margin	58.80%
Net Profit Margin	12.86%
Debt/Equity Ratio	37.8%

How did MER perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

36%

Payout Ratio

MER Stock Overview

Rewards

Risk Analysis

Merck KGaA Competitors

SWX:NOVN

CHF 182.4b

SWX:ROG

CHF 203.6b

SWX:DESN

CHF 3.2b

SWX:COPN

CHF 1.0b

Price History & Performance

Recent News & Updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

First quarter 2024 earnings released: EPS: €1.60 (vs €1.83 in 1Q 2023)

Merck KGaA, Annual General Meeting, Apr 25, 2025

Dividend of €2.20 announced

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

First quarter 2022 earnings released: EPS: €2.02 (vs €1.72 in 1Q 2021)

Upcoming dividend of €1.85 per share

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Shareholder Returns

Price Volatility

About the Company

Merck KGaA Fundamentals Summary

22.6x

2.9x

Earnings & Revenue

Dividends

1.6%

36%